Barcelona, Spain

Jose M Ribalta

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 1981.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal1 out of 834,411 
Other
 patents

Years Active: 1981

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Jose M Ribalta

Introduction

Jose M Ribalta is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of pharmaceuticals, particularly with his innovative compound that serves as an expectorant. His work exemplifies the intersection of science and practical application in medicine.

Latest Patents

Jose M Ribalta holds a patent for S-(3-Methyl-2-butenyl)cysteine, which can also be presented as a pharmaceutically acceptable salt thereof. This compound is designed to be used in various forms, including capsules, dragees, solutions, syrups, or suppositories. His invention aims to provide relief as an expectorant, showcasing his commitment to improving health outcomes.

Career Highlights

Throughout his career, Ribalta has focused on developing innovative solutions in the pharmaceutical industry. His patent reflects his dedication to creating effective medicinal compounds that can enhance patient care. With a total of 1 patent, he has established himself as a valuable contributor to the field.

Collaborations

Jose M Ribalta has worked alongside notable colleagues, including Jorge D Adsara and Silvano Casadio. Their collaborative efforts have likely enriched the research and development process, leading to advancements in their respective areas of expertise.

Conclusion

Jose M Ribalta's contributions to the pharmaceutical industry through his innovative patent highlight the importance of research and development in medicine. His work continues to impact the field positively, demonstrating the potential of scientific innovation to improve health and well-being.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…